Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Condition(s):MelanomaLast Updated:June 2, 2020Completed
Hide Studies Not Open or Pending
Condition(s):MelanomaLast Updated:June 2, 2020Completed
Condition(s):Endometrial NeoplasmsLast Updated:November 21, 2023Active, not recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:September 18, 2023Completed
Condition(s):Early Stage Non-small Cell Lung CancerLast Updated:November 13, 2020Recruiting
Condition(s):Non-small Cell Lung Cancer (NSCLC)Last Updated:March 7, 2024Recruiting
Condition(s):Metastatic Esophageal Squamous Cell CarcinomaLast Updated:March 15, 2024Recruiting
Condition(s):Advanced/Metastatic Solid TumorsLast Updated:July 11, 2022Completed
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:March 24, 2023Completed
Condition(s):Head and Neck NeoplasmsLast Updated:October 10, 2023Active, not recruiting
Condition(s):Triple Negative Breast Cancer (TNBC)Last Updated:November 9, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.